Abstract Library

#4662 A novel hormone based anti-SSTR anti-CD3 T-cell engager for the treatment of neuroendocrine tumours

Introduction: Somatostatin receptor 2 (SSTR2) is overexpressed in well-differentiated NETs.

Conference:

Presenting Author: Pelle E

Authors: Pelle E, Cives M, Chaoul N, d'Angelo G, Medina E,

Keywords: T-cell engager, immunotherapy, tumouroids,

#3804 Wide molecular analysis of PanNET revealed that only MGMT promoter methylation seemed to correlate with Temozolomide response

Introduction: Temozolomide (TMZ) is an alkylating agent and is widely used in the treatment of PanNET. So far, only the MGMT status, defined by its immunohistochemical (IHC) expression or its promoter methylation, has been proposed as predictor of response to TMZ, but its value remains controversial.

Conference:

Presenting Author: Marinoni I

Authors: Cives M, Kirchner P, Palmirotta R, Lauricella E, de Mestier L,

Keywords: PanNET, Temozolomide, MGMT,

#3758 A novel hormone-based anti-SSTR T-cell engager for the treatment of neuroendocrine tumors

Introduction: Somatostatin receptors (SSTRs) are overexpressed by well-differentiated neuroendocrine tumors (NETs).

Conference:

Presenting Author: Pelle E

Authors: Pelle E, Cives M, Medina E, Mason C, Snedal S,

Keywords: Bispecific T cell Engagers, CD3, SSTR, TILs, Immunotherapy,

#3483 A phase II single arm interventional trial evaluating the activity and safety of combination between CABOzantinib and TEMozolomide (TMZ) in lung and GEP-NENs progressive after SSAs, everolimus, sunitinib or PRRT-CABOTEM

Introduction: Cabozantinib (Cbz), a tyrosine kinase inhibitor, and Temozolomide (TMZ), an alkylating agent, show relevant clinical implications in neuroendocrine neoplasms (NENS). In glioma patients, the combination of Cbz and TMZ was well tolerated even with the addition of radiotherapy. It is possible to hypothesize a synergistic combination of Cbz and TMZ. Cbz, through the inhibition of the c-MET pathway, could enhance the sensitivity of NENs to TMZ. In addition, the intermittent metronomic schedule of TMZ has a proven anti-angiogenic activity that could be additive and/or enhance the anti-angiogenic effect of Cbz.

Conference:

Presenting Author:

Authors: Clemente O, Starita N, Cives M, Bracigliano A, Badalamenti G,

Keywords: neuroendocrine, Cabozantinb, Temozolomide, treatment, clinical trial, NEN,

#3440 Tumor neoantigens shape the immune microenvironment of panNETs: An in silico analysis

Introduction: The neoantigen landscape of panNETs has never been characterized.

Conference:

Presenting Author: Cives M

Authors: Pezzicoli G, Vegliante M, Mandriani B, Pellè E, Ciavarella S,

Keywords: neoantigens, panNET, immune microenvironment,